Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MDM2: life without p53.

S Daujat1, H Neel, J Piette

  • 1The Wellcome Trust and Cancer Research Campaign Institute of Cancer, Tennis Court Road, Cambridge, UK CB2 1QR.

Trends in Genetics : TIG
|August 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Restoration of SHIP-1 activity in human leukemic cells modifies NF-jB activation pathway and cellular survival upon oxidative stress.

Oncogene·2023
Same author

NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis.

Cell death and differentiation·2015
Same author

[NLRP3 inflammasome and visceral adipose tissue].

Revue medicale de Liege·2015
Same author

Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53.

Gene therapy·2012
Same author

PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress.

Cell death and differentiation·2012
Same author

Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.

Oncogene·2011
Same journal

Beyond housekeeping: snRNA diversity, regulation, and human disease.

Trends in genetics : TIG·2026
Same journal

Rethinking mitochondrial metabolism: Intraindividual variability meets population constraints.

Trends in genetics : TIG·2026
Same journal

A role for epigenetics in rapid adaptation.

Trends in genetics : TIG·2026
Same journal

The myth of asexual fungi.

Trends in genetics : TIG·2026
Same journal

Rethinking molecular evolution through protein language model embeddings.

Trends in genetics : TIG·2026
Same journal

Co-transcriptional splicing: Distinct phases, mutual benefits, and basis for nuclear architecture.

Trends in genetics : TIG·2026
See all related articles

The MDM2 protein, often overexpressed in tumors, can promote cancer by inhibiting p53. This study explores MDM2

Area of Science:

  • Oncology and Molecular Biology
  • Cancer Research
  • Cellular Regulation

Background:

  • MDM2 protein overexpression is linked to oncogenic potential in human tumors.
  • MDM2's primary known function is suppressing the tumor suppressor p53.
  • MDM2 possesses p53-independent activities crucial for its oncogenic function.

Purpose of the Study:

  • To investigate the p53-independent activities of the MDM2 protein.
  • To understand how cellular surveillance pathways counteract MDM2's oncogenic effects.
  • To identify other proteins targeted by MDM2 beyond p53.

Main Methods:

  • Analysis of MDM2 protein interactions.
  • Investigation of cellular pathways regulating MDM2.
  • Functional assays assessing MDM2's impact on cell proliferation and death.

Related Experiment Videos

Main Results:

  • MDM2 exhibits significant p53-independent functions.
  • Cellular surveillance mechanisms are identified that oppose deregulated MDM2.
  • MDM2 targets multiple proteins, including but not limited to p53.

Conclusions:

  • MDM2's oncogenic activity relies on both p53-dependent and p53-independent mechanisms.
  • Inactivation of surveillance pathways is necessary for MDM2's full oncogenic potential.
  • Targeting MDM2 and its associated pathways offers therapeutic strategies for cancer treatment.